logo-loader
viewMedexus Pharmaceuticals Inc

Full interview: Discovery Investment Research analyst says Medexus Pharmaceuticals has a solid business

James Gentrup, Senior Equity Analyst at micro-cap research firm Discovery Investment Research tells Proactive he thinks Canada-based Medexus Pharmaceuticals Inc (TSXV:MDP) (OTCQB:PDDPF) has a "solid" business with the company's single-dose auto-injector of methotrexate for the treatment of rheumatoid arthritis, and rates the company as a Speculative Buy with a price target of $7.65.

Gentrup says Medexus is one of only two major players who can deliver methotrexate to rheumatoid arthritis patients through its auto-injector method, and is impressed by the company's sales strategy to penetrate the US and Canadian markets.

Quick facts: Medexus Pharmaceuticals Inc

Price: 3.89 CAD

TSX-V:MDP
Market: TSX-V
Market Cap: $56.84 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Medexus Pharmaceuticals Inc named herein, including the promotion by the Company of Medexus Pharmaceuticals Inc in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Medexus Pharmaceuticals unveils jump in 1Q revenue,...

Medexus Pharmaceuticals Inc (CVE:KMDP) (OTCMKTS:PDDPF) CEO Ken d'Entremont stopped by Proactive New York to talk about the Canadian-based biopharma's fiscal first-quarter results, which showed a year-over-year jump in revenue jump to C$16.1 million, and positive EBITDA of C$0.5...

on 08/28/2019

2 min read